Drug Development KMG045/ BIO523
Programs:
Biotechnology and Bioinformatics programs (Chalmers); Molecular
Biology and Genomics/Systems Biology programs (GU).
Place in program:
Year 4/5, optional
Number of students: No limitation
Course leader:
Per Sunnerhagen, Department of Chemistry and Molecular Biology
(CMB), Göteborg University; Medicinaregatan 9C, 413 90 Göteborg /
Box 462 405 30 Göteborg
Phone: 031/786 3830; mobile 0705/294180; fax: 031/786 3801
E-mail: Per.Sunnerhagen@cmb.gu.se
Changes in the schedule and other messages regarding the course will
be distributed through E-mail and/or posted at GUL (GU) or the
Student portal (Chalmers). Handouts and literature will likewise be
available at these sites.
Length:
7.5 ECTS
Prerequisites:
Only compulsory courses in the first 3 years of the Biotechnology
program (Chalmers), the first 2 years of the Molecular Biology program
(GU), or equivalent.
Time:
Period 2, fall term 2012
Aim:
The emphasis is put on the first steps in development of a new
pharmaceutical, “drug discovery”. The premise is that this process
starts with identification of the biomolecule (“drug target”) that the
pharmaceutical is intended to affect. Examples are also given of
existing drugs, how they have been developed, and their mechanisms of
action. The course is intended to give an overview of the area, and will
cover a wide spectrum of approaches. The course is mostly theoretical,
but in certain parts practical demonstrations may be included.
Literature:
Scientific review papers, see separate list.
Accessory reading: “Genomics in Drug Discovery and Development”,
D. Semizarov and E. Blomme, 2008. John Wiley, ISBN: 978-0-47009604-8
Exam:
Written, at the end of the course. In addition, essay subjects will be
presented to be worked on individually during the course. These are
submitted at the end of the course and will be graded. The grade for the
essays and the written exam are added to give the final score.
Items in course:
Lectures, practical demonstrations, and individual projects.
Individual projects: As part of the examination, individual projects in the form of essay
subjects are used. At one specific time in the course, the subjects
(usually three), which are of the essay type, are presented. Each topic is
linked to one or more of the subjects in the course. Each student
chooses one of these topics to answer. The topics can be of e.g. the type
”given a certain problem within the domain of the course, describe how
you would go about to solve it”; or a literature study of a certain area.
The essays can be written with free consultation of the literature;
however each student must produce an individual essay, and the essays
should be produced independently of the teachers on the course.
The essays, in Swedish or English, are reported in written form,
maximum 2000 words. They are submitted on paper or per E-mail at the
end of the course and will be graded of the person who formulated the
respective topic. The grades of the individual projects and the written
exam are added to produce the final score. The individual projects
contribute about 25 % of the total.
SCHEDULE, Drug development 7.5 ECTS
Premises:
Lectures:
All lectures on Chalmers main campus, chemistry building (main
entrance, Kemigården 4).
KS31, go straight ahead from the main entrance through the doors into
the stairway and go down one level to floor 3. Enter the corridor on the
north side (the side away from the main entrance) and turn right.
KS101, turn left inside the main entrance, go through the doors into
“Forskarhus 1”. Take the elevator to floor 9 and follow the signs
leading up to floor 10 and room KS101.
Both rooms are equipped with projectors.
Demonstrations:
a) chemical screening facility
b) transgenic facility
In both cases at AstraZeneca Mölnd al. Meet in the main lobby,
Pepparedsleden 1, Mölndal.
Day
M 12/11
Times
8.00 – 9.45
Room
KS31
10.00 – 11.45
KS31
W 14/11
10.00 – 11.45
KS31
M 19/11
8.00 – 9.45
KS31
10.00 – 11.45
KS31
W 21/11
10.00 – 11.45
13.15 – 15.00
KS31
KS101
M 26/11
8.00 – 9.45
KS31
10.00 – 11.45
KS31
10.00 – 11.45
13.15 – 15.00
KS31
KS101
W 28/11
Lecture/demonstration
Introduction to the course
Genetic model organisms: Yeast
(Per Sunnerhagen, CMB, GU)
Protein as a target molecule: NMR and
screening in drug discovery
(Martin Billeter, Biochemistry, GU)
Overview of the modern process of
drug development
(Björn Löwenadler, AstraZeneca)
Global protein analysis: expression,
modification och interaction
(Anders Blomberg, CMB, GU)
Protein as a target molecule: rational
drug design
(Göran Karlsson, NMR center, GU)
Spare
Chemometrics in drug development
Johan Gottfries, CMB GU
Transgenic mice as disease models
(Margit Mahlapuu, Dept. Medicine,GU)
Screening models in drug discovery
(Johan Meuller, AstraZeneca)
Spare
Infectious disease drug discovery – an
M 3/12
W 5/12
M 10/12
W 12/12
14-18/12
M 19/12
8.00 – 9.45
AstraZeneca
10.00 – 11.45
AstraZeneca
10.00 – 11.45
KS31
13.15 – 15.00
KS101
8.00 – 9.45
KS31
10.00 – 11.45
KS31
10.00 – 11.45
KS31
13.15 – 15.00
KS101
AstraZeneca perspective
(Tomas Lundqvist, AstraZeneca)
Demonstration transgenic facility
(Mikael Bjursell, AstraZeneca)
Demonstration Automated screen and
Combinatorial chemistry
(Per-Erik Strömstedt,
AstraZeneca)
Design of pharmaceuticals directed
against proteins with known activity
(Morten Grøtli, CMB, GU)
Chemical biology: the biologist’s
perspective
(Per Sunnerhagen, CMB, GU)
Modelling drug/protein interactions
(Leif Eriksson, CMB, GU)
Strategies against development of
resistance in cancer treatment
(John Patrick Alao, CMB)
Genetic model organisms: C. elegans
(Marc Pilon, CMB, GU)
Questions before the exam
(Per Sunnerhagen)
Written exam
Submission individual projects (E-mail)